PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
The Rutgers team reported streptomycin in the medical literature in January 1944. Within months they began working with William Feldman and H. Corwin Hinshaw of the Mayo Clinic with hopes of starting a human clinical trial of streptomycin in tuberculosis. The difficulty at first was even producing enough streptomycin to do a trial, because the research laboratory methods of creating small batches had not yet been translated to commercial large-batch production. They managed to do an animal study in a few guinea pigs with just 10 grams of the scarce drug, demonstrating survival. This was just enough evidence to get Merck & Co. to divert some resources from the young penicillin production program to start work toward streptomycin production. At the end of World War II, the United States Army experimented with streptomycin to treat life-threatening infections at a military hospital in Battle Creek, Michigan. The first person who was treated with streptomycin did not survive; the second person survived but became blind as a side effect of the treatment. In March 1946, the third person—Robert J. Dole, later Majority Leader of the United States Senate and presidential nominee—experienced a rapid and robust recovery. The first randomized trial of streptomycin against pulmonary tuberculosis was carried out in 1946 through 1948 by the MRC Tuberculosis Research Unit under the chairmanship of Geoffrey Marshall (1887–1982). The trial was neither double-blind nor placebo-controlled. It is widely accepted to have been the first randomized curative trial.
24998Cf + 157N → 260105 + 4 n These results did not confirm the JINR findings regarding the 9.4 MeV or 9.7 MeV alpha decay of 260105, leaving only 261105 as a possibly produced isotope. JINR then attempted another experiment to create element 105, published in a report in May 1970. They claimed that they had synthesized more nuclei of element 105 and that the experiment confirmed their previous work. According to the paper, the isotope produced by JINR was probably 261105, or possibly 260105. This report included an initial chemical examination: the thermal gradient version of the gas-chromatography method was applied to demonstrate that the chloride of what had formed from the SF activity nearly matched that of niobium pentachloride, rather than hafnium tetrachloride. The team identified a 2.2-second SF activity in a volatile chloride portraying eka-tantalum properties, and inferred that the source of the SF activity must have been element 105. In June 1970, JINR made improvements on their first experiment, using a purer target and reducing the intensity of transfer reactions by installing a collimator before the catcher. This time, they were able to find 9.1 MeV alpha activities with daughter isotopes identifiable as either 256103 or 257103, implying that the original isotope was either 260105 or 261105.
As part of a comprehensive modernization of German radiation protection law, which is largely based on Directive 2013/59/Euratom, the provisions of the X-Ray Ordinance have been incorporated into the revised Radiation Protection Ordinance. Among many other measures, contaminated food was withdrawn from the market on a large scale. Parents were strongly advised not to let their children play in sandboxes. Some of the contaminated sand was replaced. In 1989, the Federal Office for Radiation Protection was incorporated into the Ministry of the Environment. On April 30, 2003, a new precautionary radiation protection law was promulgated to implement two EU directives on the health protection of persons against the dangers of ionizing radiation during medical exposure. The protection of workers from optical radiation (infrared radiation (IR), visible light (VIS) and ultraviolet radiation (UV)), which falls under the category of non-ionizing radiation, is regulated by the Ordinance on the Protection of Workers from Artificial Optical Radiation of 19 July 2010. It is based on the EU Directive 2006/25/EC of April 27, 2006. On March 1, 2010, the "Act on the Protection of Humans from Non-Ionizing Radiation" (NiSG), BGBl. I p. 2433, came into force, according to which the use of sunbeds by minors has been prohibited since August 4, 2009, in accordance with § 4 NiSG [Network and Information Systems Security Ordinance – NIS Ordinance] (in German) A new Radiation Protection Act came into force in Germany on October 1, 2017.
Sources: en.wikipedia.org
The New Zealand Defence Force proposes disestablishing 697 civilian roles as part of a restructuring process. 23 March: Hundreds of protesters gather outside the New Zealand Parliament to protest against the Government's plans to review the prescription of puberty blockers in "gender affirming care." New Zealand First leader and Deputy Prime Minister Winston Peters delivers a state of the nation speech at the James Hay Theatre in Christchurch, focusing on alleged wokeism and DEI issues. The event is picketed by both pro and anti-greyhound racing, pro-Palestinian and pro-Israel protesters. Police arrest 10 individuals for disrupting the event. 25 March: The High Court rejects the Whangārei District Council's bid to challenge the Director-General of Health's order to fluoridate its water supply. A magnitude 6.8 earthquake hits off the coast of Southland, producing a 10 cm (3.9 in)-tsunami. Cracks in the Dunedin Gasworks Museum were later found and may have been caused by the earthquake. The Tararua District Council issues a boil water notice in Woodville after rodent feces were found in the rafters of the town's reservoir building. 26 March: Queenstown residents protest against a decision by the Queenstown Lakes District Council to discharge treated sewage into the Shotover River. Mental Health Minister Matt Doocey acknowledges that Police accidentally sent an 11-year old autistic girl to a mental institution following a case of mistaken identity. The girl received at least two doses of anti-psychotic medicine.
=== Material characterization === Multi-parametric surface plasmon resonance, a special configuration of SPR, can be used to characterize layers and stacks of layers. Besides binding kinetics, MP-SPR can also provide information on structural changes in terms of layer true thickness and refractive index. MP-SPR has been applied successfully in measurements of lipid targeting and rupture, CVD-deposited single monolayer of graphene (3.7Å) as well as micrometer thick polymers.
=== Promoter escape === RNA polymerase then starts to synthesize the initial DNA-RNA heteroduplex, with ribonucleotides base-paired to the template DNA strand according to Watson-Crick base-pairing interactions. As noted above, RNA polymerase makes contacts with the promoter region. However these stabilizing contacts inhibit the enzyme's ability to access DNA further downstream and thus the synthesis of the full-length product. In order to continue RNA synthesis, RNA polymerase must escape the promoter. It must maintain promoter contacts while unwinding more downstream DNA for synthesis, "scrunching" more downstream DNA into the initiation complex. During the promoter escape transition, RNA polymerase is considered a "stressed intermediate." Thermodynamically the stress accumulates from the DNA-unwinding and DNA-compaction activities. Once the DNA-RNA heteroduplex is long enough (~10 bp), RNA polymerase releases its upstream contacts and effectively achieves the promoter escape transition into the elongation phase. The heteroduplex at the active center stabilizes the elongation complex. However, promoter escape is not the only outcome. RNA polymerase can also relieve the stress by releasing its downstream contacts, arresting transcription. The paused transcribing complex has two options: (1) release the nascent transcript and begin anew at the promoter or (2) re-establish a new 3′-OH on the nascent transcript at the active site via RNA polymerase's catalytic activity and recommence DNA scrunching to achieve promoter escape.
===== Macroscopic viscous flow ===== Macroscopic viscous flow fields can direct self-assembly of a random solution of particles into ordered crystals via the shear-assisted nucleation mechanism. However, the flow-induced self-assembly often occurs far from thermodynamic equilibrium and leads to amorphous aggregates of nanoparticles through a mechanism by which the shear flow field overcomes the repulsive energy barrier which stabilizes the nanoparticles against self-assembly in the absence of flow. The assembled particles aggregates tend to disassemble due to flow-induced breakup or when the flow is stopped or removed if the interparticle bonds are weak. Shear flows are also useful for jammed suspensions or random close packing. As these systems begin in nonequilibrium conditions, flow fields are useful in that they help the system relax towards a more ordered equilibrium. Flow fields are also useful when dealing with complex matrices that themselves exhibit rheological behavior. Flow can induce anisotropic viseoelastic stresses, which helps to overcome the matrix and cause self-assembly.
Sources: en.wikipedia.org
According to Kate Brown, the plutonium production plants at Hanford and Mayak in Russia, over a period of four decades, "both released more than 200 million curies of radioactive isotopes into the surrounding environment—twice the amount expelled in the Chernobyl disaster in each instance". Most of this radioactive contamination over the years were part of normal operations, but unforeseen accidents did occur and plant management kept this secret, as the pollution continued unabated. In 2004, a safe was discovered during excavations of a burial trench at the Hanford nuclear site. Inside the safe were various items, including a large glass bottle containing a whitish slurry which was subsequently identified as the oldest sample of weapons-grade plutonium known to exist. Isotope analysis by Pacific Northwest National Laboratory indicated that the plutonium in the bottle was manufactured in the X-10 Graphite Reactor at Oak Ridge during 1944.
Additional antiandrogen therapy is not necessarily required if testosterone levels are in the normal female range or if the person has undergone orchiectomy. However, individuals with testosterone levels in the normal female range and with persisting androgen-dependent skin and/or hair symptoms, such as acne, seborrhea, oily skin, or scalp hair loss, can potentially still benefit from the addition of an antiandrogen, as antiandrogens can reduce or eliminate such symptoms.
Actor Jerome Flynn, who starred in Game of Thrones as Bronn, was born in Bromley. Gus Lobban and Jamie Bulled of the band Kero Kero Bonito grew up in Bromley. Deborah Linsley, the victim of one of Britain's most high-profile unsolved murders in 1988, grew up in Bromley. Richard Reid, also known as the "Shoe Bomber", was born and lived in Bromley. He was convicted of the 2001 shoe bomb attempt. In the 20th century, the Parish Church of St Peter and St Paul produced, in quick succession, three Church of England Bishops: Henry David Halsey – Bishop of Carlisle, Philip Goodrich – Bishop of Worcester, David Bartleet – Bishop of Tonbridge. Sculptor Nicholas Cornwell and Maisy James the Big Brother 12 housemate. Sometime before 1881 the engineer and industrialist Richard Porter moved to Beckenham where he remained until his death in 1913. Hanif Kureishi, the writer and filmmaker was born here, and spent a significant part of his youth, here. His first novel The Buddha of Suburbia was loosely based on his life here and the people he lived and met here. Comedian Frankie Boyle claims to be a former resident and has described Bromley as a 'lobotomy made out of bricks'. The comedian Chris Addison currently lives in Bromley, as does tennis player Emma Raducanu. Scottish education secretary Michael Russell MSP was born and spent the early years of his life in Bromley. Member of the Senedd Paul Rock was born in Bromley. Bromley is the home of video game developer Splash Damage.
Intrahepatic cholestasis of pregnancy (ICP) is an acute cause of cholestasis that manifests most commonly in the third trimester of pregnancy. It affects 0.5–1.5% of pregnancies in Europe and the US and up to 28% in women of Mapuche ethnicity in Chile. ICP is characterized by severe pruritus and elevated serum levels of bile acids as well as transaminases and alkaline phosphatase. These signs and symptoms resolve on their own shortly after delivery, though they may reappear in subsequent pregnancies for 45–70% of women. In the treatment of ICP, current evidence suggests ursodeoxycholic acid (UDCA), a minor secondary bile acid in humans, is the most effective drug for reducing pruritus and improving liver function. The etiology of ICP is multifactorial and likely involves hormonal, genetic, and environmental factors. Several observations suggest estrogen plays a major role: ICP begins in the third trimester, when estrogen levels are highest, resolves after estrogen levels return to normal post-delivery, and occurs with higher incidence in multiple pregnancies, where estrogen levels are more elevated than usual. Although estrogen's exact pathomechanism in ICP remains unclear, several explanations have been offered. Estrogen may induce a decrease in the fluidity of the hepatic sinusoidal membrane, leading to a decrease in the activity of basolateral Na+/K+-ATPase. A weaker Na+ gradient results in diminished sodium-dependent uptake of bile acids from venous blood into hepatocytes by the sodium/bile acid cotransporter.
== Adverse effects == The most common adverse reactions include upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat). An increased risk of fractures, including serious fractures, was observed in people treated with apitegromab. Apitegromab may cause fetal harm and may affect reproductive function.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.